Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00055227.xml
Nephrologie aktuell 2024; 28(01): 31-35
DOI: 10.1055/a-2187-3490
DOI: 10.1055/a-2187-3490
Schwerpunkt
Nephrologie
Diuretika bei arterieller Hypertonie
Mehr denn je unverzichtbar im Therapiemanagement
ZUSAMMENFASSUNG
Seit Jahrzehnten sind Diuretika bei der antihypertensiven Therapie nicht wegzudenken und werden millionenfach verordnet. In den letzten Jahren wurden verschiedentliche Studien publiziert, in denen der Stellenwert von Diuretika in der antihypertensiven Therapie untersucht worden ist. Daraufhin wurde die Bedeutung von Diuretika in den zuletzt publizierten Hypertonieleitlinien großer Fachgesellschaften betont, was in der Folge auch zu Zulassungserweiterungen führen könnte. Nach der Veröffentlichung einer dänischen Studie bestanden zwischenzeitlich Unsicherheiten hinsichtlich des mit der Einnahme von Hydrochlorothiazid verbundenen Risikos für Hauttumoren. Diese konnten mittlerweile besser eingeordnet werden, sodass Patienten weiterhin von der Therapie profitieren können. Beim Blick in die Zukunft darf man gespannt auf die neuen Entwicklungen insbesondere in Bezug auf die neuen nichtsteroidalen Mineralokortikoid-Rezeptor-Antagonisten (MRA) und ihren Beitrag zur antihypertensiven Therapie sein.
Publication History
Article published online:
14 February 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Zhou B, Carrillo-Larco RM, Danaei G. et al Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021; 398: 957-980 DOI: 10.1016/S0140-6736(21)01330-1.
- 2 Neuhauser H KR, Born S. 12-Monats-Prävalenz von Bluthochdruck in Deutschland. J Health Monit 2017; 02: 57-63 DOI: 10.17886/RKI-GBE-2017–007.
- 3 Freis ED. Treatment of hypertension with chlorothiazide. J Am Med Assoc 1959; 169: 105-108 DOI: 10.1001/jama.1959.03000190007002.
- 4 MacDonald TM, Williams B, Webb DJ. et al Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017; 06: e006986 DOI: 10.1161/jaha.117.006986.
- 5 Intersalt Cooperative Research Group Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1988; 297: 319-328 DOI: 10.1136/bmj.297.6644.319.
- 6 Mozaffarian D, Fahimi S, Singh GM. et al Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371: 624-634 DOI: 10.1056/NEJMoa1304127.
- 7 He FJ, Tan M, Ma Y. et al Salt reduction to prevent hypertension and cardiovascular disease: JACC State-of-the-Art Review. J Am Coll Cardiol 2020; 75: 632-647 DOI: 10.1016/j.jacc.2019.11.055.
- 8 He FJ, Markandu ND, Sagnella GA. et al Plasma sodium: ignored and underestimated. Hypertension 2005; 45: 98-102 DOI: 10.1161/01.HYP.0000149431.79450.a2.
- 9 Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res 2015; 116: 1007-1021 DOI: 10.1161/CIRCRESAHA.116.303596.
- 10 Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021; 99: S1-S87 DOI: 10.1016/j.kint.2020.11.003.
- 11 Mancia G, Kreutz R, Brunström M. et al 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; 41: 1874-2071 DOI: 10.1097/HJH.0000000000003480.
- 12 Puleo F, Kim K, Frame AA. et al Sympathetic regulation of the NCC (sodium chloride cotransporter) in Dahl salt-sensitive hypertension. Hypertension 2020; 76: 1461-1469 DOI: 10.1161/HYPERTENSIONAHA.120.15928.
- 13 Pojoga LH, Yao TM, Sinha S. et al Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol 2008; 294: H1258-H1265 DOI: 10.1152/ajpheart.01014.2007.
- 14 Officers TA. Group CftACR. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997 DOI: 10.1001/jama.288.23.2981.
- 15 Bundesinstitut für Arzneimittel und Medizinprodukte. Rote-Hand-Brief zu Hydrochlorothiazid (HCT): Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)] (17.10.2018). Im Internet. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2018/rhb-hydrochlorothiazid.html. Stand: 09.10.2023
- 16 Pedersen SA, Gaist D, Johannesdottir Schmidt SA. et al Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78: 673-681.e9 DOI: 10.1016/j.jaad.2017.11.042.
- 17 Pottegård A, Hallas J, Olesen M. et al Hydrochlorothiazide use is strangly associated with risk of lip cancer. J Intern Med 2017; 282: 322-331 DOI: 10.1111/joim.12629.
- 18 Götzinger F, Wilke T, Hardtstock F. et al Association of hydrochlorothiazide treatment compared with alternative diuretics with overall and skin cancer risk: a propensity-matched cohort study. J Hypertens 2023; 41: 926-933 DOI: 10.1097/hjh.0000000000003414.
- 19 Copland E, Canoy D, Nazarzadeh M. et al Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol 2021; 22: 558-570 DOI: 10.1016/S1470-2045(21)00033-4.
- 20 Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 2017; 35: 922-944 DOI: 10.1097/hjh.0000000000001276.
- 21 Hripcsak G, Suchard MA, Shea S. et al Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020; 180: 542-551 DOI: 10.1001/jamainternmed.2019.7454.
- 22 Ishani A, Cushman WC, Leatherman SM. et al Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med 2022; 387: 2401-2410 DOI: 10.1056/NEJMoa2212270.
- 23 Agarwal R, Sinha AD, Cramer AE. et al Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 2021; 385: 2507-2519 DOI: 10.1056/NEJMoa2110730.
- 24 Dussol B, Moussi-Frances J, Morange S. et al A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012; 14: 32-37 DOI: 10.1111/j.1751-7176.2011.00564.x.
- 25 Dussol B, Moussi-Frances J, Morange S. et al A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 2004; 20: 349-353 DOI: 10.1093/ndt/gfh650.
- 26 Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone and in combination in chronic renal failure. J Cardiovasc Pharmacol 1995; 26: 394-400 DOI: 10.1097/00005344-199509000-00008.
- 27 Yin J, Wagner DJ, Prasad B. et al Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K. Am J Physiol Renal Physiol 2019; 317: F805-F814 DOI: 10.1152/ajprenal.00141.2019.
- 28 Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. J Hum Hypertens 2014; 28: 463-468 DOI: 10.1038/jhh.2013.140.
- 29 Pitt B, Zannad F, Remme WJ. et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717 DOI: 10.1056/nejm199909023411001.
- 30 Williams B, MacDonald TM, Morant S. et al Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-2068 DOI: 10.1016/S0140-6736(15)00257-3.
- 31 Agarwal R, Ruilope LM, Ruiz-Hurtado G. et al Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens 2023; 41: 295-302 DOI: 10.1097/hjh.0000000000003330.
- 32 Bryan W, Mancia G, Spiering W. et al 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104 DOI: 10.1093/eurheartj/ehy339.